跳至主要内容
临床试验/CTRI/2021/02/031480
CTRI/2021/02/031480已完成3 期

Targeted-release Budesonide therapy versus conservative management in Immunoglobulin A nephropathy:An open label randomised controlled trial

Department of NephrologyIPGMER SSKM Hospital0 个研究点目标入组 53 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
53

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Biopsy verified IgA nephropathy
  • 24 hour urinary protein more than or equal to one gram
  • eGFR of atleast 45 ml per minute per 1.73 square metre or more
  • informed consent

排除标准

  • Uncontrolled blood pressure ( treated or untreated) defined as systolic blood pressure more than or equal to 160 mmHg and diastolic blood pressure more than or equal to 100 mmHg.
  • Patients who are pregnant or breast feeding their child or unwilling to use adequate contraception during the study (only women of child bearing potential).
  • Liver disease , Diabetes mellitus ,current or history of malignancy.
  • History or presence of psychological or psychiatric illness.
  • Acute or chronic infections.
  • IFTA in renal biopsy more than 30%.

研究者

发起方
Department of NephrologyIPGMER SSKM Hospital

相似试验

to know the effect of capsule budesonide on protein... | 临床试验